# KEYMAKER-U03 (NCT04626518)

> Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab/quavonlimab; favezelimab/pembrolizumab; pembrolizumab plus MK-4830
- Indication: second-line metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04626518
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Pembrolizumab; MK-4830; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Favezelimab/Pembrolizumab
- Enrollment: 263
- Primary outcome: Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
- Primary outcome: Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
- Primary outcome: Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
- Primary outcome: Efficacy Phase: Number of participants who experienced DLTs
- Primary outcome: Efficacy Phase: Number of participants who experience one or more AEs
- Primary outcome: Efficacy Phase: Number of participants who discontinue study treatment due to an AE
- Primary outcome: Efficacy Phase: Objective response rate (ORR)

## Indexed commentary on KEYMAKER-U03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keymaker-u03-nct04626518